Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- International Day of Play 2025 - 9th June 2025
- Urgent EU Action to Safeguard Access to Medicines - 8th June 2025
- Common gene variant doubles dementia risk for men - 8th June 2025